Skip to content
Catalyst

knowcompounds(4S)-4-hydroxy-L-isoleucine

Specimen compound

(4S)-4-hydroxy-L-isoleucine

4-Hydroxyisoleucine, the amino acid of fenugreek seed, sold as a fenugreek extract standardised to it. A trial of a whole fenugreek seed or extract not stated as standardised to it is filed under Trigonella foenum-graecum.

Description on record

fig. 1(4S)-4-hydroxy-L-isoleucine · findings by direction and evidence strength

↑ raised 2 findings in 1 endpoint · ↓ lowered 5 in 5

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
0
Limited
0
Very limited
0
Insufficient
7

How to read these marks

Fig. 2 (4S)-4-hydroxy-L-isoleucine CHEBI:79079 6 endpoints 7 findings
×1.60
Labels
CompoundInspector

(4S)-4-hydroxy-L-isoleucine

Most findings

  • HDL cholesterol×2
  • Body mass×1
  • Interleukin-6 concentration×1
  • LDL cholesterol×1
  • Total cholesterol (TC)×1
  • Tumour necrosis factor alpha concentration×1

36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. HDL cholesterol
  2. Body mass
  3. Interleukin-6 concentration
  4. LDL cholesterol
  5. Total cholesterol (TC)
  6. Tumour necrosis factor alpha concentration
fig. 3 · 6 endpoints · 7 findingsno endpoint contested

02 · findings

What (4S)-4-hydroxy-L-isoleucine moved, and by how much

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction

7 shown

  1. HDL cholesterolMoved: raisesEvidence: Insufficientreplicated ×1Paper: PMID 201408042010
    Who
    C57BL/KsJ-db/db mice, a model of type II diabetes
    Dose studied
    4-hydroxyisoleucine 50 mg/kg orally

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.”

    Quoted verbatim from Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice.animal · not in humansPermalink
  2. Body massMoved: lowersEvidence: InsufficientPaper: PMID 409173562025
    Who
    male C57BL/6 mice with high-fat-diet-induced obesity (10 weeks HFD), high-fat diet continued in both arms
    Dose studied
    4-hydroxyisoleucine 200 mg/kg/day by intraperitoneal injection in 0.3 ml saline per 30 g body weight for six weeks; control HFD mice received saline injections

    Consistent with previous reports, we observed that 4-HIL treatment significantly reduced the body weight of mice in the HFD group compared to HFD mice without treatment.”

    Quoted verbatim from Potential role of 4-hydroxyisoleucine in enhancing fertility in male mice with diet-induced obesity.animal · not in humans · 6 weeksPermalink
  3. HDL cholesterolMoved: raisesEvidence: Insufficientreplicated ×1Paper: PMID 186801212009
    Who
    streptozotocin-induced diabetic rats (described as a type 2 diabetes model)
    Dose studied
    not reported

    In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).”

    Quoted verbatim from The effect of fenugreek 4-hydroxyisoleucine on liver function biomarkers and glucose in diabetic and fructose-fed rats.animal · not in humansPermalink
  4. LDL cholesterolMoved: lowersEvidence: InsufficientPaper: PMID 201408042010
    Who
    C57BL/KsJ-db/db mice, a model of type II diabetes
    Dose studied
    4-hydroxyisoleucine 50 mg/kg orally

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.”

    Quoted verbatim from Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice.animal · not in humansPermalink
  5. Total cholesterol (TC)Moved: lowersEvidence: InsufficientPaper: PMID 201408042010
    Who
    C57BL/KsJ-db/db mice, a model of type II diabetes
    Dose studied
    4-hydroxyisoleucine 50 mg/kg orally

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.”

    Quoted verbatim from Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice.animal · not in humansPermalink
  6. Interleukin-6 concentrationMoved: lowersEvidence: InsufficientPaper: PMID 409173562025
    Who
    male C57BL/6 mice with high-fat-diet-induced obesity, high-fat diet continued in both arms
    Dose studied
    4-hydroxyisoleucine 200 mg/kg/day by intraperitoneal injection for six weeks; control HFD mice received saline injections

    In addition, inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα), were assessed, and their serum and testis concentrations were found to be reduced in 4-HIL treated mice compared to those in HFD mice (Supplementary Figures S2C, D).”

    Quoted verbatim from Potential role of 4-hydroxyisoleucine in enhancing fertility in male mice with diet-induced obesity.animal · not in humans · 6 weeksPermalink
  7. Tumour necrosis factor alpha concentrationMoved: lowersEvidence: InsufficientPaper: PMID 409173562025
    Who
    male C57BL/6 mice with high-fat-diet-induced obesity, high-fat diet continued in both arms
    Dose studied
    4-hydroxyisoleucine 200 mg/kg/day by intraperitoneal injection for six weeks; control HFD mice received saline injections

    In addition, inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα), were assessed, and their serum and testis concentrations were found to be reduced in 4-HIL treated mice compared to those in HFD mice (Supplementary Figures S2C, D).”

    Quoted verbatim from Potential role of 4-hydroxyisoleucine in enhancing fertility in male mice with diet-induced obesity.animal · not in humans · 6 weeksPermalink

No dose is advised.

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · on the label · 11 products

Labelled products

Source: NIH DSLD · Ingredient: (4S)-4-hydroxy-L-isoleucine · 11 products · Declared amount per serving: 66–100 mg

2 labels state an amount9 do not

  • EvogenGlycoJect Unflavoredamount not statedper 26 gDSLD:31052
  • EvogenGlycoJect Watermelonamount not statedper 27 gDSLD:31050
  • Gaspari NutritionSuperPump 250 Blue Raspberry4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80711
  • Gaspari NutritionSuperPump 250 Boardwalk Cotton Candy4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80661
  • Gaspari NutritionSuperPump 250 Country Life Pink Lemonade4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80699
  • Gaspari NutritionSuperPump 250 Country Life Pink Lemonade4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80746
  • Gaspari NutritionSuperPump 250 Rainbow Italian Ice4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80706
  • Gaspari NutritionSuperPump 250 Rainbow Italian Ice4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80756
  • Gaspari NutritionSuperPump 250 Strawberry Kiwi4-Hydroxyisoleucine, Fenugreek Extract, from Fenugreek seed extract, seedamount not statedper 6.5 gDSLD:80759
  • Musclegen ResearchFreak Mutant Lime66 mgper 1 scoopDSLD:213489
  • PEScienceMass-NP4-Hydroxyisoleucine, standardized from Fenugreek seed extract, seed100 mgper 3 capsulesDSLD:230704

Label record: NIH Office of Dietary Supplements · CC0

04 · the record

Sources

20

papers screened for (4S)-4-hydroxy-L-isoleucine

admitted
3
read and discarded
7
not read yet
10

The screening record, every paper and why

Documented interactions
None reported

Sources cited

3 papers · 7 findings

Show every paper citedHide the papers cited
183Endpoints measured, not recorded as findingsEvery row, on one page
10Papers indexed under (4S)-4-hydroxy-L-isoleucine